Skip to main content
Caplight Logo









En Carta Diagnostics

En Carta Diagnostics

Private
ParisHealthcare & Life Scienceshttps://www.encarta.bio/

Last Round

Seed

Jul 10, 2026

Est. Valuation

$33M

Total Funding Raised

$7.34M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

En Carta Diagnostics is a biotechnology company that develops rapid point-of-care molecular diagnostic kits with an initial focus on the early diagnosis of Lyme disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

molecular diagnosticspoint of care testingPOCTLyme disease testsynthetic biologysynbiorapid diagnosticsinfectious disease diagnosticsequipment-free diagnosticsPCR-equivalent accuracyno cold chainpaper-based diagnosticscustom diagnostic developmentat-home screeningFDA Breakthrough Devicetoehold switch sensors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

En Carta Diagnostics Comparables

Compare En Carta Diagnostics with similar companies based on industry and business-model similarity.

En Carta Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Anavasi Diagnostics
79%
ExGen Dx
77%
Visby Medical
71%

En Carta Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJul 10, 2026
Pre SeedMay 22, 2024

Key People

Founding team and executive leadership

Margot Karlikow

Co-founder - CTO

Founding Team

En Carta Diagnostics Investors

Notable investors and investment history

En Carta Diagnostics investors
InvestorRounds
Paris Biotech SantéPre Seed
50 PartnersPre Seed, Seed
Blue Forest VenturesSeed
CentraleSupélec VentureSeed, Pre Seed
Ring CapitalSeed
BpifranceSeed
PC'up IncubatorPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 59% MoM, from 1.9K to 3K.

  • Jul 10, 2026

    $5.7M round led by Blue Forest Ventures

En Carta Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

En Carta Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about En Carta Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range12
Year Founded2022
Last FundingJul 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?